Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance

References

• Asuncion M, Calvo RM and San Millan JLet al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–8
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ and Kahsar-Miller Met al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078–82
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–9
   PubMed Web of Science ®Google Scholar
• Nestler JE and Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617–23
   PubMed Web of Science ®Google Scholar
• Nestler JE and Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–9
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB and Rosenfield RLet al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Bjorntorp P. The android woman – a risky condition. J Intern Med 1996;239:105–10
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Cífková R and Jirkovská Aet al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003;18:980–4
   PubMedGoogle Scholar
• Talbott E, Clerici A and Berga SLet al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol (England) 1998;51:415–22
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D and Clerici Aet al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–6
   PubMed Web of Science ®Google Scholar
• Wild RA, Alaupovic P and Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women: the association with insulin resistance. Am J Obstet Gynecol 1992;166:1191–6
   PubMed Web of Science ®Google Scholar
• Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98:27S–32S
   PubMed Web of Science ®Google Scholar
• Paradisi G, Steinberg HO and Hempfling Aet al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410–15
   PubMed Web of Science ®Google Scholar
• Lakhani K, Constantinovici N and Purcell WMet al. Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet 2000;356:1166–7
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Speirs A and Gould GWet al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742–6
   PubMed Web of Science ®Google Scholar
• Larner J. Multiple pathways in insulin signaling – fitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167–71
   Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E and Ostlund RE Jr, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovarian syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ and Baillargeon JPet al. Effect of D-chiro-inositol in lean women with the polycystic ovarian syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Chiu TT, Rogers MS and Law ELet al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591–6
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V and Baillargeon JPet al. Myo-inositol in patients with polycystic ovarian syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700–3
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V and Baillargeon JPet al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–4
   PubMed Web of Science ®Google Scholar
• Raffone E, Rizzo P and Benedetto V. Insulin sensitizer agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010;26:275–80
   PubMed Web of Science ®Google Scholar
• Zacchè MM, Caputo L and Filippis Set al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–13
   PubMed Web of Science ®Google Scholar
• Venturella R. Assesment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol 2010;64:239–43
   Google Scholar
• Costantino D, Minozzi G, Minozzi E and Guaraldi C. Metabolic and hormonal effects of myoinositol in women with polycystic ovarian syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–10
   PubMed Web of Science ®Google Scholar
• Gerli S, Papaleo E, Ferrari A and Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–56
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Prati A and Santagni Set al. Differential insulin response to myo-inositol administration in obese polycystic ovarian syndrome patients. Gynecol Endocrinol 2012;28:969–73
   PubMed Web of Science ®Google Scholar
• Minozzi M, Costantino D, Guaraldi C and Unfer V. The effect of a combination therapy with myo-inositol and combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine and clinical parameterd in polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:920–4
   PubMed Web of Science ®Google Scholar
• D’Anna R, Di Benedetto V and Rizzo Pet al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012;28:440–2
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S and Hamer Tet al. Methformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D and Legro RSet al; PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626–32
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ and Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in polycystic ovary syndrome. J Ped Endocrinol 2000;13:1295–8
   PubMed Web of Science ®Google Scholar
• Iuorno MJ and Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin N Am 2001;28:153–64
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F and Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Minozzi M, D’Andrea G and Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579–82
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM and Papini Fet al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013;29:375–9
   PubMed Web of Science ®Google Scholar
• Minozzi M, Nordio M and Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013;17:537–40
   PubMed Web of Science ®Google Scholar